WUMC Cancer and Leukemia Group B

自1986年以来，华盛顿大学一直是CALGB的主要成员机构。在过去的六年里，巴恩斯-犹太医院和华盛顿大学医学院的西特曼癌症中心(SCC)已经成长为全国领先的NCI癌症中心之一。2004年被指定为综合癌症中心，2006年被指定为国家综合癌症网络(NCCN)的第20个成员，Siteman增强了其协作和翻译基础设施，这增加了华盛顿大学CALGB的科学能力。在上一个拨款周期中，3名华盛顿大学教职员工担任CALGB科学委员会主席，另外11名教职员工在科学委员会任职。2003-2008年间，WUMS的教职员工主持了26项治疗及相关科学方案，并与他人合著了74篇CALGB出版物。在整个赠款期间，WUMS继续增长良好，每年都在CALGB机构中排名前5。WUMS 在这一赠款期间，所有CALGB试验的应计利润平均为293/年，治疗试验的平均应计患者/年为140人。我们的投资组合仍然多样化，在乳房、Gl、Gu、白血病和淋巴瘤研究方面获得了出色的收益。2007-2008年的几位新教师将进一步增强我们为CALGB科学使命做出贡献的能力，特别是在乳腺癌、药理学和实验疗法、胸部肿瘤学、白血病和淋巴瘤领域。WUMS调查人员和CALGB白血病组织库之间的合作正在进行中，并继续努力识别AML的关键突变。下一个资助周期的目标包括1)继续努力增加应计项目，特别是CALGB试验的少数应计项目，2)WUMS研究人员更多地参与CALGB科学委员会，特别是白血病、PET、GL和成像委员会，3)增加我们非常有经验和杰出的CRA参与审计和CRA委员会，以及4)改善WUMS和CALGB之间关于SCC可用资源的沟通，这将增强CALGB的科学使命，特别是我们进行高质量相关研究的能力。

Washington University has been a CALGB main member institution since 1986. Over the last six years, the Siteman Cancer Center (SCC) at Barnes-Jewish Hospital and Washington University School of Medicine (WUMS) has grown to become one of the leading NCI Cancer Centers nationally. Designated in 2004 as a Comprehensive Cancer Center and in 2006 as the 20th member of the National Comprehensive Cancer Network (NCCN), Siteman has enhanced its collaborative and translational infrastructure, which has increased the scientific capacity of the CALGB at Washington University. During the last grant cycle, 3 Washington University faculty members chaired CALGB scientific committees, and 11 additional faculty members served on scientific committees. From 2003-2008, WUMS faculty chaired 26 treatment and correlative science protocols and co-authored 74 CALGB publications. WUMS has continued to accrue well throughout the entire grant period, ranking in the top 5 among CALGB institutions every year. WUMS accrual to all CALGB trials during this grant period averaged 293/year with an average of 140 patients/year accrued to therapeutic trials. Our portfolio remains diverse with excellent accruals to breast, Gl, GU, leukemia and lymphoma studies. Several newfaculty recruits in 2007-2008 will further enhance our ability to contribute to the CALGB scientific mission, specifically in the areas of breast cancer, pharmacology and experimental therapeutics, thoracic oncology, leukemia, and lymphoma. Collaborations are ongoing between WUMS investigators and the CALGB leukemia tissue bank, with continued efforts to identify key mutations in AML. Goals for the next grant cycle include 1) continued efforts to increase accruals, particularly minority accruals to CALGB trials, 2) increased involvement of WUMS investigators in CALGB scientific committees specifically leukemia, PET, Gl, and imaging 3) increased involvement of our very experienced and outstanding CRAs in the audit and CRA committees, and 4) improved communication between WUMS and CALGB regarding resources available at the SCC that will enhance the scientific mission of CALGB, specifically our ability to perform high quality correlative studies.